Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$50.66

0.12 (0.24%)

09:55
09/21/17
09/21
09:55
09/21/17
09:55

Alkermes CEO highlights study showing opioids reduce life expectancy

Alkermes CEO Richard Pops said via Twitter, "New study shows opioids shortened U.S. life expectancy over 15 yrs. Issue isn't theoretical, it's horribly real." Alkermes manufactures and markets Vivitrol, an injectable medicine used to prevent relapse to opioid dependence after opioid detox. Reference Link

  • 18

    Oct

ALKS Alkermes
$50.66

0.12 (0.24%)

06/30/17
JEFF
06/30/17
NO CHANGE
Target $69
JEFF
Buy
Alkermes announced positive schizophrenia data, says Jefferies
Jefferies analyst Biren Amin says Alkermes last night announced positive data from the ENLIGHTEN-1 study testing ALKS-3831 patients with schizophrenia for four weeks. The study demonstrated a numerically better improvement in PANSS compared to olanzapine and statistical significant improvements versus placebo in PANSS and CIGS, Amin tells investors in a research note. He adds, however, that the more important data to assess clinical relevance will report later this year and the weight gain data will report in the first half of 2018. The analyst keeps a Buy rating on Alkermes with a $69 price target.
06/30/17
COWN
06/30/17
NO CHANGE
Target $63
COWN
Outperform
Alkermes trial results 'solidly positive' despite some confusion, says Cowen
Cowen analyst Chris Shibutani says ALKS 3831 "cleared the efficacy bar" for new drug application filing in its first pivotal efficacy study. Importantly, 3831 also demonstrated similar efficacy to the olanzapine comparator arm, Shibutani tells investors in a research note. He expects 3831 to show its differentiated profile of reduced weight gain compared to olanzapine in the second pivotal weight study, expected in mid-2018. The analyst believes last night created some investor confusion, but points out the ENLIGHTEN-1 study was not designed to demonstrate any relative reduction in weight gain with ALKS 3831 versus olanzapine. He keeps an Outperform rating on Alkermes with a $63 price target. The shares in after-hours trading last night dropped 3% to $56.00.
07/27/17
JEFF
07/27/17
NO CHANGE
Target $69
JEFF
Buy
Alkermes quarter in-line, focus now on ALKS 5461, says Jefferies
Jefferies analyst Biren Amin views Alkermes' Q2 results as in-line and says the focus now turns to initiating and completing the new drug application filing this for ALKS 5461 in depression. The analyst continues to see regulatory risk for ALKS 5461 and models a 50% discount rate to revenue estimates. Amin adds that Vivitrol and Aristada performed better in Q2. The analyst keeps a Buy rating on Alkermes with a $69 price target. Alkermes, which also disclosed this morning receipt of a subpoena from a U.S. Attorney regarding Vivitrol, is down 4% to $55.10 in afternoon trading.
07/27/17
LEER
07/27/17
NO CHANGE
Target $59
LEER
Market Perform
Leerink drops Alkermes depression drug approval odds to 40%
Leerink analyst Paul Matteis lowered his odds of approval for ALKS 5461, Alkermes' depression drug candidate, to 40% from 50% after the company learned that the FDA will be looking at MADRS-10 as the key assessment of efficacy, not MADRS-6, the primary endpoint in the FORWARD-5 trial. The analyst says he's now "incrementally more cautious on approvability." Matteis dropped his price target for Alkermes shares to $59 from $61 and reiterates a Market Perform rating on the name following the Q2 earnings report.

TODAY'S FREE FLY STORIES

ROKU

Roku

$22.19

-0.83 (-3.61%)

09:02
10/17/17
10/17
09:02
10/17/17
09:02
Hot Stocks
Roku expands further into Latin America, to launch two players in region »

Roku, Inc. announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEOT

Neothetics

$0.52

-0.0206 (-3.81%)

09:02
10/17/17
10/17
09:02
10/17/17
09:02
Hot Stocks
Neothetics, Evofem Biosciences announce all-stock merger »

Neothetics (NEOT) and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$22.19

-0.83 (-3.61%)

09:01
10/17/17
10/17
09:01
10/17/17
09:01
Hot Stocks
Roku launches Roku Express in Canada »

Roku, Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABEO

Abeona Therapeutics

$16.70

0.6 (3.73%)

09:01
10/17/17
10/17
09:01
10/17/17
09:01
Syndicate
Abeona Therapeutics 5M share Spot Secondary priced at $16.00 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 23

    Oct

  • 17

    Oct

NFLX

Netflix

09:00
10/17/17
10/17
09:00
10/17/17
09:00
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

09:00
10/17/17
10/17
09:00
10/17/17
09:00
General news
Fed funds futures are modestly lower, having unwound early gains »

Fed funds futures are…

09:00
10/17/17
10/17
09:00
10/17/17
09:00
General news
Industrial Production to be reported at 09:15 »

September Industrial…

09:00
10/17/17
10/17
09:00
10/17/17
09:00
General news
Industrial Production Capacity Utilization Rate to be reported at 09:15 »

September Industrial…

ACN

Accenture

$139.09

-0.11 (-0.08%)

08:59
10/17/17
10/17
08:59
10/17/17
08:59
Hot Stocks
Accenture enters into exclusive negotiations to acquire Altima »

Accenture has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

JNJ

Johnson & Johnson

$136.12

-0.31 (-0.23%)

08:59
10/17/17
10/17
08:59
10/17/17
08:59
Earnings
Johnson & Johnson backs FY17 revenue view $75.9B-$76.2B, consensus $75.83 »

Guidance in constant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

LRCX

Lam Research

$192.36

2.46 (1.30%)

08:59
10/17/17
10/17
08:59
10/17/17
08:59
Recommendations
Lam Research analyst commentary  »

Lam Research added to US…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

JNJ

Johnson & Johnson

$136.12

-0.31 (-0.23%)

08:57
10/17/17
10/17
08:57
10/17/17
08:57
Hot Stocks
Breaking Hot Stocks news story on Johnson & Johnson »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

08:56
10/17/17
10/17
08:56
10/17/17
08:56
General news
Redbook Store Sales data reported »

Week of 10/14 Redbook…

SRPT

Sarepta

$50.73

0.16 (0.32%)

08:56
10/17/17
10/17
08:56
10/17/17
08:56
Recommendations
Sarepta analyst commentary  »

Sarepta approaching…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

NFLX

Netflix

$202.68

3.19 (1.60%)

, GE

General Electric

$23.36

0.38 (1.65%)

08:55
10/17/17
10/17
08:55
10/17/17
08:55
Options
Notable open interest changes for October 17th »

Monday's total…

NFLX

Netflix

$202.68

3.19 (1.60%)

GE

General Electric

$23.36

0.38 (1.65%)

CMCSA

Comcast

$36.61

0.6 (1.67%)

BAC

Bank of America

$26.24

0.41 (1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 01

    Nov

08:55
10/17/17
10/17
08:55
10/17/17
08:55
General news
The U.S. trade price report beat estimates »

The U.S. trade price…

NOW

ServiceNow

$121.40

-0.89 (-0.73%)

08:55
10/17/17
10/17
08:55
10/17/17
08:55
Conference/Events
ServiceNow to hold a forum »

NowForum 2017 is being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 25

    Oct

  • 26

    Oct

  • 11

    Dec

GSM

Ferroglobe

$14.56

0.39 (2.75%)

08:55
10/17/17
10/17
08:55
10/17/17
08:55
Conference/Events
Ferroglobe to hold investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 14

    Nov

  • 15

    Nov

MSBI

Midland States

$33.03

-0.07 (-0.21%)

08:55
10/17/17
10/17
08:55
10/17/17
08:55
Conference/Events
Midland States to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 27

    Oct

  • 15

    Nov

HPE

HP Enterprise

$14.86

-0.03 (-0.20%)

08:53
10/17/17
10/17
08:53
10/17/17
08:53
Initiation
HP Enterprise initiated  »

HP Enterprise initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 11

    Dec

JNJ

Johnson & Johnson

$136.12

-0.31 (-0.23%)

08:51
10/17/17
10/17
08:51
10/17/17
08:51
Hot Stocks
Johnson & Johnson says Puerto Rico hurricane had limited impact on company »

Says impact was limited…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

PX

Praxair

$141.29

-0.92 (-0.65%)

08:51
10/17/17
10/17
08:51
10/17/17
08:51
Hot Stocks
Praxair signs long-term agreement to supply nitrogen to GLOBALFOUNDRIES »

Praxair has signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

ERII

Energy Recovery

$8.21

0.02 (0.24%)

08:49
10/17/17
10/17
08:49
10/17/17
08:49
Initiation
Energy Recovery initiated  »

Energy Recovery initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 16

    May

JNJ

Johnson & Johnson

$136.12

-0.31 (-0.23%)

08:49
10/17/17
10/17
08:49
10/17/17
08:49
Hot Stocks
Breaking Hot Stocks news story on Johnson & Johnson »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

CSX

CSX

$52.84

0.01 (0.02%)

08:49
10/17/17
10/17
08:49
10/17/17
08:49
Hot Stocks
CSX expects Q4 volume to be neutral »

CSX has a favorable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 29

    Oct

  • 30

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.